Current Status of BTKi Treatment for CLL/SLL in China

Last updated: July 14, 2024
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphocytic Leukemia, Chronic

Treatment

BTK inhibitor

Clinical Study ID

NCT06508684
PICASSO
  • Ages 18-80
  • All Genders

Study Summary

BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years;

  • Patients with a confirmed diagnosis of CLL/SLL;

  • Received BTK inhibitor treatment between February 2023 and February 2024.

Exclusion

Exclusion Criteria:

  • Patients with other types of lymphoma;

  • Cases deemed unsuitable for inclusion in this study by the investigators.

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: BTK inhibitor
Phase:
Study Start date:
July 13, 2024
Estimated Completion Date:
July 12, 2025

Connect with a study center

  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjin, Jiangsu 210029
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.